AstraZeneca plans to build $1.5 billion drug making facility in Singapore
HQ Team May 20, 2024: AstraZeneca plans to build a $1.5 billion facility to make antibody-drug conjugates in Singapore, the company announced in.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team May 20, 2024: AstraZeneca plans to build a $1.5 billion facility to make antibody-drug conjugates in Singapore, the company announced in.
HQ Team May 13, 2024: Pfizer and AstraZeneca will invest about $1 billion separately in France to set up and expand facilities, Finance.
HQ Team March 20, 2024: Anglo-Swedish drugmaker, AstraZeneca will acquire clinical-stage Fusion Pharmaceuticals for $2 billion in cash to get access to the.
HQ Team February 17, 2024: The USFDA has cleared AstraZeneca’s Tagrisso with chemotherapy for treatment in adult patients with non-small cell lung cancer..
HQ Team December 22, 2023: Anglo-Swedish AstraZeneca Inc., and US-based Ionis Pharmaceuticals, announced the FDA has granted its nod for Wainua drug to.
HQ Team November 29, 2023: The University of Cambridge announced a partnership with AstraZeneca and the Medical Research Council to set up a functional genomics laboratory.
HQ Team November 1, 2023: AstraZeneca signed a $245 million deal with a French clinical-stage biotechnology firm, Cellectis, to speed up therapeutics in.
HQ Team July 29, 2023: Alexion, AstraZeneca Rare Disease, an arm of AstraZeneca group, has signed a $1 billion pact with Pfizer for.
HQ Team June 9, 2023: An advisory committee of the USFDA has given a “favourable benefit-risk profile” for Sanofi and AstraZeneca’s experimental drug.
HQ Team June 9, 2023: AstraZeneca, a British-Swedish pharmaceutical company, has signed a deal, worth more than $2 billion, with Quell Therapeutics to.